Clinical study on Xu’s Danmajia Formula in the treatment of chronic obstructive pulmonary disease with syndrome of turbid phlegm obstructing lung

LU Chenghua; XU Beiqi; XU Xiangqian; GUO Xiaoyan; ZHANG Shaoyan; LU Junyan; XUE Honghao; ZHANG Huiyong

doi:10.16305/j.1007-1334.2018.10.011

您当前的位置：

首页 >

文章列表页 >

Clinical study on Xu’s Danmajia Formula in the treatment of chronic obstructive pulmonary disease with syndrome of turbid phlegm obstructing lung

更新时间：2022-08-31

- Clinical study on Xu’s Danmajia Formula in the treatment of chronic obstructive pulmonary disease with syndrome of turbid phlegm obstructing lung
- Shanghai Journal of Traditional Chinese Medicine Vol. 52, Issue 10, Pages: 41-44(2018)
- 作者机构：
  
  1. 上海中医药大学附属龙华医院肺病科,上海,200032
  2. 上海中医药大学附属龙华医院徐小圃学术思想研究室,上海,200032
  3. 海军军医大学第三附属医院中西医结合科,上海,201805
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2018.10.011
  CLC：
扫描看全文
LU Chenghua, XU Beiqi, XU Xiangqian, et al. Clinical study on Xu’s Danmajia Formula in the treatment of chronic obstructive pulmonary disease with syndrome of turbid phlegm obstructing lung. [J]. Shanghai Journal of Traditional Chinese Medicine 52(10):41-44(2018)
DOI：

LU Chenghua, XU Beiqi, XU Xiangqian, et al. Clinical study on Xu’s Danmajia Formula in the treatment of chronic obstructive pulmonary disease with syndrome of turbid phlegm obstructing lung. [J]. Shanghai Journal of Traditional Chinese Medicine 52(10):41-44(2018) DOI： 10.16305/j.1007-1334.2018.10.011.

摘要

目的：观察徐氏胆麻荚方治疗痰浊壅肺型慢性阻塞性肺疾病(慢阻肺)的临床疗效。方法：将106例痰浊壅肺型慢阻肺患者随机分为治疗组和对照组,每组53例。治疗组予徐氏胆麻荚方治疗,对照组予桂龙咳喘宁胶囊治疗。两组疗程均为10天,观察临床疗效及安全性,随访3个月内急性加重情况,比较中医证候积分、CAT评分及肺功能相关指标第1 秒用力呼气量占预计值百分比(FEV,1,%)、第一秒用力呼气容积占用力肺活量百分比(FEV,1,/FVC)的变化情况。结果：①最终完成试验者96例,治疗组50例,对照组46例。②治疗组、对照组总有效率分别为98.0%、63.0%；组间临床疗效比较,治疗组明显优于对照组(P,<,0.05)。③治疗前后组内比较,治疗组FEV,1,%水平有升高趋势,但差异无统计学意义(P,>,0.05),FEV,1,/FVC水平差异无统计学意义(P,>,0.05)；对照组FEV,1,%、FEV,1,/FVC水平差异无统计学意义(P,>,0.05)。组间治疗后比较,FEV,1,%、FEV,1,/FVC水平差异无统计学意义(P,>,0.05)。④两组受试者在试验期间均未出现用药相关不良反应,治疗前后安全性常规检查均未见异常。随访期间,治疗组未出现慢阻肺急性加重的患者,对照组有2例患者出现喘促加剧的现象,经支气管扩张剂及激素治疗后好转。结论：徐氏胆麻荚方治疗痰浊壅肺型慢阻肺的临床疗效满意,可显著缓解患者的临床症状,提高患者生活质量。

Abstract

Objective:To observe the clinical efficacy of Xu’s Danmajia Formula in treating chronic obstructive pulmonary disease (COPD) with syndrome of turbid phlegm obstructing lung. Methods106 COPD patients with syndrome of turbid phlegm obstructing lung were randomly divided into the treatment group and control group, 53 cases in each group. The treatment group was treated with Xu’s Danmajia Formula, while the control group was treated with Guilong Kechuanning Capsule, with a course of 10 days. The clinical efficacy and safety and the acute exacerbation within 3 months of follow-up were observed. The changes on TCM syndrome score, CAT score, percentage of forced expiratory volume in the first second to the predicted value (FEV,1,%), and percentage of forced expiratory volume in the first second to the forced vital capacity (FEV,1,/FVC) were compared. Results:①Finally 96 patients completed the trial, among 50 cases in the treatment group and 46 cases in the control group. ②The total effective rates were 98.0% in the treatment group and 63.0% in the control group, the clinical efficacy of the treatment group was significantly better than that of the control group (P,<,0.05). ③Compared with treatment before, the level of FEV,1,% in the treatment group showed an increasing tendency after treatment, but with no statistically significant difference (P,>,0.05). And in the treatment group, there was no statistically significant difference on FEV,1,/FVC level between treatment before and after (P,>,0.05). In the control group, there were no statistically significant differences on the levels of FEV,1,% and FEV,1,/FVC between treatment before and after (P,>,0.05). After treatment, there were no statistically significant differences on the levels of FEV,1,% and FEV,1,/FVC between the two groups (P,>,0.05). ④No drug-related adverse reactions were observed in both groups during the trial, and no abnormality in routine safety examination was observed before and after treatment. During the follow-up, no acute exacerbation of chronic obstructive pulmonary disease occurred in the treatment group, and 2 patients in the control group showed asthma exacerbation and were alleviated after treatment with bronchodilators and hormones. Conclusion:Xu’s Danmajia Formula in treating chronic obstructive pulmonary disease with syndrome of turbid phlegm obstructing lung shows satisfactory clinical efficacy, which can significantly relieve the clinical symptoms and improve the quality of life of patients.

关键词

慢性阻塞性肺疾病痰浊壅肺证胆麻荚方徐仲才陆鸿元

Keywords

chronic obstructive pulmonary diseasesyndrome of turbid phlegm obstructing lungDanmajia FormulaXu ZhongcaiLu Hongyuan

references

Views

219

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Distribution rule of TCM syndrome elements in chronic obstructive pulmonary disease with lung cancer

Research progress on relationship between skeletal muscle atrophy and apoptosis in COPD based on theory of “spleen dominating muscles” and intervention effect of traditional Chinese medicine

Research progress on mechanism of traditional Chinese medicine on pulmonary disease / hypoxia induced pulmonary hypertension

Clinical study on the treatment of patients with stable chronic obstructive pulmonary disease with Bufei Yishen Decoction combined with conventional western medicine

Clinical study of Mahuang Shengma Decoction in treatment of chronic obstructive pulmonary disease with obstructive sleep apnea-hypopnea syndrome

Related Author

No data

Related Institution

Suzhou Hospital of Traditional Chinese Medicine

Shanghai Pulmonary Hospital， Tongji University

Pneumology Department， Yueyang Hospital of Integrated Traditional Chinese and Western Medicine， Shanghai University of Traditional Chinese Medicine

Infectious Disease Department， Shanghai Zhoupu Hospital

Pneumology Department， Fengxian Branch of Longhua Hospital Affiliate to Shanghai University of Traditional Chinese Medicine

⁰